It started with one question no one could answer.
A mother in a hospital bed. A body sending signals no one could read. And a son who decided that medicine should never again have to guess.
The origin
The misread that started a company.
Lars's mother lives with chronic neuropathic pain. During a long hospitalization, her pain was quietly driving her body's signals down.
Her doctors looked at those signals and read a failing heart. So they treated the heart. What followed was a cascade of wrong medications and adverse reactions that kept her in the hospital for weeks, each new drug chasing a problem that was never there.
It was never her heart. It was her pain. And no one in that hospital had a way to measure it. The most important fact about her condition, how her body was actually responding, was sitting in plain sight in the rhythm of her own pulse. What looked like noise was the answer. No one was equipped to read it.
The question that built Bardel is the one her doctors could not answer: was the treatment working, or was it doing harm? For her, and for roughly 76 million patients treated every year with no objective data on their response, the honest answer was a shrug.
What we believe
The phenotype is the constant. Everything else is configuration.
Every intervention produces a physiological signature in how the body responds. That signature is the constant. The drug, the dose, the disease, the device, all of it is configuration. Read the response, and you can read whether any treatment is working.
Measurement is the bridge
Measurement is the bridge between hope and proof.
One capability, measurement, unlocks everything downstream. It is the chain that turns a guess into a system.
- When you can measure it, you can bill for it.
- When you can bill for it, clinicians adopt it.
- When clinicians adopt it, patients get better outcomes.
Why now
Medicine is finally being asked to prove the response.
Mandatory outcome measurement is arriving. Remote therapeutic monitoring and value-based care are turning "did it work" from a question clinicians could avoid into one they are paid, and required, to answer.
Every route has dosimetry except the response
We can measure the dose that goes in with precision. Until now, no one could measure what the body did with it. Bardel closes the loop with objective, real-time treatment-response measurement.
The signal was already there
The body has always reported how it is responding, in the structure of its own signal, not just its volume. Decades of peer-reviewed cardiac research settled the science. The infrastructure to read it in real time was missing. We built it.
Where we are
A thesis, turned into traction.
The road so far
From a question to a category.
-
2024
The concept
One question, born at a hospital bedside, becomes a thesis: medicine should be able to see how a body is responding to any treatment, in real time.
-
Early 2025
Team formed, first clinical advisor
The founding team comes together. Dr. Karyemaitre Aliffe joins as the first clinical advisor, and the clinical methodology behind Trak+ begins to take shape.
-
Mid 2025
Building the moat
Work begins on the intellectual property behind the platform's approach to objective treatment-response measurement, the foundation of a defensible position.
-
Late 2025
Live in the field
75 devices live, more than 850 therapeutic sessions captured, 78% monthly retention, across 33 states. The thesis is no longer a thesis. It is data.
-
2026
Building a category
As of 2026, the platform is live across 33 states, advised by leaders in pain medicine, pharma, payers, and finance, from the clinician who founded Princeton Pain Management to operators who led a national drug launch and ran a multibillion-dollar Medicare business. A guess is becoming a standard.
Build the future of medicine with us
Medicine has been flying blind. It does not have to anymore.
See the platform, or explore a partnership.